Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results
Portfolio Pulse from
Cryoport, Inc. (NASDAQ: CYRX) reported its financial results for Q4 and FY 2024, with revenue reaching $228.4 million, aligning with company guidance. The company's Commercial Cell & Gene Therapy revenue increased by 20% year-over-year to $26 million, and it supported a record 701 global clinical trials by the end of 2024.
March 04, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cryoport's FY 2024 revenue of $228.4 million met company guidance, with a notable 20% increase in Commercial Cell & Gene Therapy revenue. The company supported a record 701 global clinical trials.
Cryoport's financial results meeting guidance and the significant growth in Cell & Gene Therapy revenue are positive indicators for the company's performance. Supporting a record number of clinical trials further strengthens its market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100